AspenBio Announces Dismissal of Class Action and Chipman Lawsuits
AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced that the United States District Court for Colorado has dismissed and entered judgment without prejudice in both the class action lawsuit (Case No. 11-cv-00165-REB-KMT) against the company and certain of its former or current officers and directors, and the Mark Chipman lawsuit (Case No. 11-cv-00163-REB-KMT) against the company.
"We are very pleased with the court's decisions," stated Steve Lundy, President and CEO of AspenBio. "We continue to execute on our priority of advancing AppyScore™ toward commercialization."
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.